Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
File(s)2003545.full.pdf (380.14 KB)
Published version
Author(s)
Larsson, Susanna C
Burgess, Stephen
Gill, Dipender
Type
Journal Article
Abstract
Respiratory disease is a main feature of severe COVID-19, and the potential of IL-6 receptor blockade to increase risk of pneumonia warrants vigilance and caution in their application to treat COVID-19.
Date Issued
2021-01-14
Date Acceptance
2020-10-29
Citation
European Respiratory Journal, 2021, 57 (1), pp.1-3
ISSN
0903-1936
Publisher
European Respiratory Society
Start Page
1
End Page
3
Journal / Book Title
European Respiratory Journal
Volume
57
Issue
1
Copyright Statement
Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
http://creativecommons.org/licenses/by-nc/4.0/
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/33214204
PII: 13993003.03545-2020
Subjects
C-Reactive Protein
COVID-19
European Continental Ancestry Group
Genetic Predisposition to Disease
Hospitalization
Humans
Mendelian Randomization Analysis
Pneumonia
Polymorphism, Single Nucleotide
Receptors, Interleukin-6
Respiratory Insufficiency
SARS-CoV-2
Severity of Illness Index
Humans
Pneumonia
Respiratory Insufficiency
Genetic Predisposition to Disease
C-Reactive Protein
Receptors, Interleukin-6
Hospitalization
Severity of Illness Index
Polymorphism, Single Nucleotide
European Continental Ancestry Group
Mendelian Randomization Analysis
COVID-19
SARS-CoV-2
Respiratory System
11 Medical and Health Sciences
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2021-01-14